National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$39.00
add to cart

Rights & Permissions

topleft topright

Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C (2010)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "2 Surveillance." Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press, 2010.

Please select a format:

BibTeX EndNote RefMan


Page
53
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C

BOX 2-5

CDC Hepatitis C Virus Infection Case Definition (Past or Present)

Clinical description:

Most HCV-infected persons are asymptomatic. However, many have chronic liver disease, which can range from mild to severe including cirrhosis and liver cancer.


Laboratory criteria for diagnosis:

  • Anti-HCV positive (repeat reactive) by EIA, verified by an additional more specific assay (e.g., RIBA for anti-HCV or nucleic acid testing for HCV RNA),

or

  • HCV RIBA positive,

or

  • Nucleic acid test for HCV RNA positive,

or

  • Report of HCV genotype,

or

  • Anti-HCV screening-test-positive with a signal to cut-off ratio predictive of a true positive as determined for the particular assay (e.g., 3.8 for the enzyme immunoassays) as determined and posted by CDC.

Case classification:

Confirmed: a case that is laboratory confirmed and that does not meet the case definition for acute hepatitis C.

Probable: a case that is anti-HCV positive (repeat reactive) by EIA and has ALT or SGPT values above the upper limit of normal, but the anti-HCV EIA result has not been verified by an additional more specific assay or the signal to cutoff ratio is unknown.


Abbreviations: CDC, Centers for Disease Control and Prevention; HCV, hepatitis C virus; EIA, enzyme immunoassay; RIBA, recombinant immunoblot assay; RNA, ribonucleic acid; ALT or SGPT, alanine aminotranferase.

SOURCE: CDC, 2009a.

zyme immunoassay (EIA). A repeatedly reactive EIA is followed by a more specific assay to detect viremia, such as the recombinant immunoblot assay (RIBA) for anti-HCV, or by nucleic acid testing for HCV RNA. In some cases, an EIA with a high signal-to-cutoff ratio predictive of a true positive will be used in the place of a confirmatory RIBA. However, all confirmed anti-HCV test results should be followed by a test for the presence of HCV

Page
53